The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

Dr. Greg Shay is a pediatric pulmonologist, a children's lung specialist, with the NGO MedGlobal who has just returned from a ...

The incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir compared with daily oral emtricitabine-tenofovir disoproxil fumarate.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...